
|Videos|June 16, 2017
The Complexity of the PARP Inhibitor Landscape in Ovarian Cancer
Author(s)Douglas A. Levine, MD
Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, and director, Divison of Gynecologic Oncology, NYU Langone Medical Center, discusses the impact of PARP inhibitors on the landscape of ovarian cancer.
Advertisement
Advertisement
Related Content
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
2
FDA Approves SimpleScreen Blood Test for CRC Screening
3
Monthly IVIG Lowers Recurrent Infection Rates in Patients With CLL
4
Dato-DXd Plus Pembrolizumab Elicits Responses Even With Low PD-L1
5


























